Carl June Weighs in on FDA’s Cell and Gene Therapy Round Table
Carl June, MD, is the Richard W. Vague Professor in Immunotherapy at Penn Medicine .
Moderna’s RSV Vaccine Receives Expanded FDA Approval
The FDA has expanded approval for Moderna's mRNA-based RSV vaccine based on Penn IP.
Dr. Jim Wilson’s Gene Therapy Work with Gemma Biotherapeutics Profiled by the Philadelphia Inquirer
Gemma Biotherapeutics was co-founded in 2024 by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director's Professor in Penn Medicine.
Cerespectus and Vasowatch Join HiveBio’s Inaugural Cohort
HiveBio has selected its inaugural cohort of underrepresented biotech founders.
Cerespectus Accepted into Science Center’s Capital Readiness Program
Cerespectus was co-founded by Bryan Pukenas, MD, Associate Professor of Radiology in Penn Medicine.
MavriX Bio Announces FDA Clearance for Gene Therapy Trial
MavriX will initiate a clinical trial of a gene therapy for Angelman syndrome.
Capstan Therapeutics Begins Phase 1 Trial of CAR-T Therapy for Autoimmune Disease
Capstan Therapeutics, a biotechnology company spun out of Penn, has initiated its Phase 1 trial of an in vivo CAR-T therapy.
World’s First Patient Treated with Personalized CRISPR Gene Editing Therapy through Penn Medicine and CHOP Collaboration
In a history-making breakthrough, a baby diagnosed with a rare genetic disorder was successfully treated with a customized CRISPR gene editing therapy.
Penn Medicine’s Jake Brenner Develops State-of-the-art DNA-Delivery Technology
By safely delivering therapeutic DNA to cells, this technology has the potential to transform treatment for common chronic diseases.
Cesar de la Fuente’s AI Breakthroughs Could Help Predict the Next Pandemic
Recently, Dr. de la Fuente’s lab has been working on developing new antibiotics and exploring prehistoric proteins that could be repurposed to fight modern diseases